GLP-3 Weight Loss Drugs: What Triple Agonists Mean
Table of Contents
“GLP-3” has become a popular search term for a new generation of triple-agonist weight-loss medications, but it is not the name of an actual human hormone. The term usually refers to drugs designed to activate three metabolic pathways at once: GLP-1, GIP, and glucagon.
Retatrutide is the best-known triple-agonist candidate currently being studied for obesity treatment. Because it remains investigational and is not FDA-approved, patients should distinguish between established GLP-1 or dual-agonist medications and newer triple-agonist drugs still being evaluated in clinical trials.
Quick Answer: What Does GLP-3 Mean?
“GLP-3” is an informal online term—not a recognized human hormone or drug class—for triple-agonist drugs targeting GLP-1, GIP, and glucagon. Retatrutide is investigational, not FDA-approved. In a Phase 3 trial in adults with type 2 diabetes, Lilly reported average 80-week weight reductions of 20.9% with 12 mg retatrutide and 9.4% with Ozempic 2 mg; results are not individual predictions.
Quick Overview
- “GLP-3” is not a real hormone.
- It typically refers to triple-agonist drugs targeting GLP-1, GIP, and glucagon receptors.
- Retatrutide is the leading triple-agonist candidate in development.
- In phase 2 clinical trials, the highest dose of retatrutide produced about 24 percent average weight loss at 48 weeks.
- Retatrutide is still in clinical trials and not FDA-approved.
| Medication Type | What It Means | Main Target | Safety Note |
|---|---|---|---|
| GLP-1 medications | Medications that target the GLP-1 receptor | Appetite, glucose regulation, gastric emptying | Requires provider review and monitoring |
| GLP-2 medications | Drugs related to GLP-2 pathways | Intestinal and gut-related pathways | Not typically used for mainstream obesity treatment |
| “GLP-3” / triple agonists | Informal term for drugs targeting three metabolic receptors | GLP-1, GIP, and glucagon | Retatrutide remains investigational and is not FDA-approved |
What Patients Should Know Before Starting Treatment
Before starting any GLP-1, dual agonist, or triple-agonist style weight loss treatment, patients should understand that these medications are not interchangeable. Semaglutide, tirzepatide, and investigational triple agonists work through different pathways, have different approval statuses, and require different medical screening.
Patients should know:
- “GLP-3” is an informal online term, not an official hormone name
- Retatrutide is still investigational and not FDA-approved
- Semaglutide and tirzepatide options should be reviewed with a provider
- Side effects may include nausea, vomiting, diarrhea, constipation, appetite changes, or dehydration
- Eligibility depends on health history, medications, labs, weight goals, and risk factors
- Long-term success usually requires nutrition, resistance training, hydration, and follow-up care
- Unregulated online products may be unsafe, mislabeled, or improperly dosed
A medical weight loss consultation helps determine which treatment options are appropriate and which options should be avoided.
For patients comparing medically supervised options, learn more about medical weight loss in Tucson at Tucson Wellness MD, including provider evaluation, treatment selection, monitoring, and long-term support.
GLP-3 vs GLP-1: What Is the Difference?
GLP-1 medications target one main receptor involved in appetite control, stomach emptying, and glucose regulation. Triple-agonist medications target three pathways at once: GLP-1, GIP, and glucagon. That is why people online often call them “GLP-3,” even though GLP-3 is not an official hormone or drug class.
| Category | GLP-1 Medications | Triple-Agonist Drugs |
|---|---|---|
| Common examples | Semaglutide-based medications | Retatrutide, currently investigational |
| Receptors targeted | GLP-1 | GLP-1, GIP, and glucagon |
| Main goal | Appetite control and glucose support | Broader metabolic support through multiple pathways |
| Approval status | Some GLP-1 medications are FDA-approved for weight loss or diabetes | Retatrutide is not FDA-approved and remains under study |
| Safety note | Requires medical screening and monitoring | Requires clinical oversight and should not be purchased from unregulated sources |
What Triple-Agonist Drugs Do
Triple-agonists are designed to stimulate three metabolic pathways simultaneously.
GLP-1 Receptor
- Reduces appetite
- Slows stomach emptying
- Improves post-meal glucose control
This pathway is already used in approved medications such as semaglutide.
GIP Receptor
- Influences insulin signaling
- Works alongside GLP-1 to regulate appetite and metabolism
This pathway is part of tirzepatide’s mechanism.
Glucagon Receptor
- May increase energy expenditure
- Influences fat metabolism
Adding glucagon receptor activity is what distinguishes triple-agonists from dual-agonists.
The goal of combining all three is greater weight loss and broader metabolic effects.
What Do the Latest Retatrutide Results Show?
Retatrutide is an investigational triple agonist that targets the GLP-1, GIP, and glucagon receptors. On October 28, 2026, Eli Lilly reported topline Phase 3 results from TRANSCEND-T2D-2, a head-to-head trial in adults with type 2 diabetes. At 80 weeks, the company reported average weight reductions of 19.5% with 9 mg retatrutide and 20.9% with 12 mg, compared with 9.4% with Ozempic 2 mg.
These are trial averages from a specific study population, not a prediction of an individual’s results. The comparison was against Ozempic 2 mg in a diabetes trial; it should not be treated as a direct comparison with every approved medication or dose used for weight management. These are company-reported topline results, and retatrutide remains investigational and not FDA-approved. Read Lilly’s trial announcement.
Retatrutide Safety, Side Effects, and FDA Status
Retatrutide is still being studied. Trial findings describe what researchers observed in specific study participants; they do not establish how every person would respond or the full long-term safety profile.
What Side Effects Have Been Reported in Clinical Trials?
In Lilly’s October 2026 report on the Phase 3 TRANSCEND-T2D-2 trial, commonly reported adverse events included diarrhea, nausea, constipation, vomiting, and indigestion. Lilly reported that side effects led to treatment discontinuation in 4.8% of participants receiving 9 mg retatrutide and 7.9% receiving 12 mg, compared with 2.7% receiving Ozempic 2 mg.
These results came from a specific trial in adults with type 2 diabetes. They are not a complete list of possible risks or a prediction of how an individual will respond. Lilly said detailed results would be presented and published later. Read Lilly’s trial announcement.
What Do the Current Safety Findings Tell Us?
The available findings show what was observed during the reported trial. They do not answer every question about individual risk or long-term use. Retatrutide remains investigational, and its safety and effectiveness are still being evaluated.
Is Retatrutide FDA-Approved or Available?
No. As of November 2, 2026, retatrutide is not FDA-approved for routine treatment. The FDA also states that retatrutide cannot be used in compounding under federal law. Avoid products marketed online as retatrutide and review the FDA’s information about unapproved GLP-1 drugs.
What Should Patients Discuss With a Provider?
Because retatrutide is not an approved treatment, patients can ask a provider about currently available options that may fit their health history and goals. Learn more about medical weight loss at Tucson Wellness MD.
Comparison With Current Approved Medications
| Medication type | Receptors targeted | Current status |
|---|---|---|
| Semaglutide | GLP-1 | Some formulations are FDA-approved for specific indications |
| Tirzepatide | GLP-1 and GIP | FDA-approved for specific indications |
| Retatrutide | GLP-1, GIP, and glucagon | Investigational; not FDA-approved |
Regulatory Status and Access
Retatrutide is not FDA-approved and remains in clinical trials. Patients should avoid products sold online as “retatrutide” or “GLP-3” injections outside legitimate clinical research or approved medical channels, because product identity, purity, dosing, and sterility may be uncertain.
Retatrutide is:
- In phase 3 clinical trials
- Not FDA-approved
- Only available through clinical trials
Consumers should avoid products marketed online as retatrutide outside research settings. Counterfeit and unregulated products pose serious safety risks.
Body Composition During Weight Loss
Large weight loss from any method includes both:
- Fat mass
- Lean tissue
Research on GLP-1–based medications shows lean tissue can represent roughly 25–40 percent of total weight lost without resistance training and adequate protein intake.
This highlights the importance of:
- Strength training
- Adequate protein
- Medical monitoring
Patients focused on fat loss while preserving lean tissue can also review fat loss injection options at Tucson Wellness MD alongside appropriate nutrition, protein intake, and resistance training.
Bottom Line
“GLP-3” refers to triple-agonist medications like retatrutide that target GLP-1, GIP, and glucagon receptors.
Early clinical trials show substantial weight loss potential. However, retatrutide is not FDA-approved and remains investigational.
Weight-loss medications should always be considered within a comprehensive plan that includes:
- Nutrition
- Resistance training
- Medical supervision
- Monitoring of body composition
If you are exploring advanced weight-loss therapies, consult a qualified healthcare provider to determine what is appropriate for your health profile.
If you want a safer plan built around your health history, labs, and goals, explore our medical weight loss consultation options at Tucson Wellness MD.
Explore Medically Supervised Weight-Loss Options
Retatrutide remains investigational and is not FDA-approved. If you are considering weight management care, a provider can review your health history, goals, and currently available options to determine what may be appropriate.
Contact Tucson Wellness MDFrequently Asked Questions
What does GLP-3 mean in weight loss?
“GLP-3” is an informal term used online for triple-agonist drugs that target GLP-1, GIP, and glucagon receptors. It is not the name of a recognized human hormone or official drug class.
Is retatrutide FDA-approved?
No. As of November 2, 2026, retatrutide remains investigational and is not FDA-approved. Trial findings do not mean that it is approved or available as a routine prescription weight-loss medication.
How much weight did retatrutide reduce in the latest Phase 3 trial?
In Lilly’s October 2026 report on TRANSCEND-T2D-2, adults with type 2 diabetes had average weight reductions of 19.5% with 9 mg retatrutide and 20.9% with 12 mg at 80 weeks. The reported result was 9.4% with Ozempic 2 mg. These were trial averages in a specific population, not guaranteed individual outcomes.
Can you buy retatrutide?
Retatrutide is not FDA-approved for routine use. FDA says retatrutide cannot be used in compounding under federal law. Patients should avoid products marketed online as retatrutide and discuss approved treatment options with a licensed healthcare provider.
How is retatrutide different from semaglutide and tirzepatide?
Semaglutide targets the GLP-1 receptor, while tirzepatide targets GLP-1 and GIP receptors. Retatrutide targets GLP-1, GIP, and glucagon receptors, but remains investigational and is not FDA-approved.
